The pharmaceutical intervention on the interaction between intracellular signaling pathways mediated by Ca 
. How these two L-type VACC blockers can enhance, instead of reducing, the Ca2+-dependent contractile and secretory responses? We properly gave a response to this "calcium paradox" in 2013 through the Ca2+/cAMP signaling interaction [8] . Huntington´s diseases [15, 16] . Briefly, the reduction of Ca2+ influx through L-type VACC produced by CCB enhances the adenylyl cyclase activity (and consequently elevating cAMP levels, please see figure 1 ). These CCB- In addition, many reports have shown that increase of cytosolic cAMP concentration stimulates neuroprotective effects [18, 19] . Thus, elevating cAMP levels by handling Ca2+/cAMP signaling interaction could reduce neuronal death triggered by cytosolic Ca2+ overload [15, 16] . Then, the pharmacological handling of the Ca2+/cAMP signalling interaction produced by combination of the L-type CCB prescribed in the antihypertensive therapy, and cAMP-enhancer compounds prescribed in the anti-depressive therapy such as rolipram, could be a novel pharmacological strategy for enhancing neurotransmission in neurological, and psychiatric disorders, resulting of neurotransmitter release deficit, and neuronal death [15, 16] . Figure 1 illustrates how the pharmacological modulation of the Ca2+/cAMP signaling interaction could be used in human therapy.
Pharmaceutical Intervention On
In fact, it was demonstrated that the prescription of L-type CCB reduces motor symptoms, and reduces progressive neuronal death in animal model of Parkinson´s disease, indicating that L-type CCB are potentially viable neuroprotective pharmaceuticals [20] .
Intriguingly, a 1-decade study involving thousands senile hypertensive patients demonstrated that prescription of L-type CCB reduced blood pressure, and risk of dementia, in hypertensive patients, indicating that these pharmaceuticals could be clinically used to treat neurodegenerative diseases [21] . These results for the neuroprotective effects of CCB have been reinvestigated in thousands elderly hypertensive patients with memory dysfunction [22] . These studies concluded that patients who have taken CCB had their risk of cognitive dysfunction decreased, such as Alzheimer´s disease [22] . These findings reinforce the idea that reduction of cytosolic Ca2+ overload produced by L-type CCB due to blockade of Ca2+ influx could be an alternative pharmacological goal to reduce, or prevent, neuronal death in neurodegenerative diseases.
Due to involvement of the Ca2+ and cAMP signaling pathways in the regulation of the cellular differentiation process, it is possible that the pharmacological modulation of the Ca2+/cAMP signaling interaction could stimulate the cellular differentiation in stem cells [15, 16] . In this case, this pharmacological In conclusion, the Ca2+/cAMP signaling interaction may dramatically impact on medical research and therapeutics, stimulating the development of new pharmacological strategies for the therapy of human diseases, including: neurodegenerative diseases, and yet cellular therapy using stem cells for combating diseases related to aging.
